Rhythm Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGRhythm Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 77), indicating performance broadly in line with the market. Earnings contraction of 2% provides fundamental context to the price action. However, price is extended 23% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $100.63 | +13.74% | ABOVE |
| 50 SMA | $93.42 | +22.52% | ABOVE |
| 100 SMA | $91.72 | +24.80% | ABOVE |
| 150 SMA | $96.64 | +18.44% | ABOVE |
| 200 SMA | $98.33 | +16.40% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RYTM in an uptrend right now?
RYTM has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is RYTM overbought or oversold?
RYTM's RSI (14) is 73. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is RYTM outperforming the market?
RYTM has a Relative Strength (RS) Rating of 77 out of 99. RYTM is performing about average compared to the market.
Where is RYTM in its 52-week range?
RYTM is trading at $114.46, which is 94% of its 52-week high ($122.20) and 87% above its 52-week low ($64.65).
How volatile is RYTM?
RYTM has a Beta of 1.04 and 52-week volatility of 57%. It's more volatile than the S&P 500 - expect bigger swings.